Navigation Links
Mercury Therapeutics Patents Filed
Date:3/31/2008

rapid progress MTI has made in the design and synthesis of novel AMPK activators, I am optimistic that we will be filing an IND by the end of 2009 to initiate clinical trials focusing on Type-2 diabetics who no longer respond to metformin or other available oral therapies."

About Mercury Therapeutics, Inc. (http://www.mtipharm.com)

MTI is an early stage drug discovery company focusing on the development of small molecule candidates against a number of selected protein kinase drug targets in metabolic diseases and oncology. MTI's main focus is on the discovery and development of orally active small molecule activators of AMPK, a well-validated though largely unexploited, protein kinase drug target in metabolic disease. While a number of anti-diabetic drugs currently on the market, including metformin (Glucophage(R)) and pioglitazone (Actos(R)), act indirectly to activate AMPK, MTI is seeking to develop the first orally available direct AMPK activator. The potential indications of a successful AMPK targeted drug include Type-2 diabetes, hyperlipidemia, obesity, metabolic syndrome and endocrine cancers.

MTI was launched in 2001, and has an exclusive license to a patent from Dartmouth College and St. Vincent's Institute for Biomedical Research in Melbourne, Australia for AMP activated protein kinase (AMPK). In June 2001, MTI launched its R&D operations following execution of a collaboration agreement with Aventis, AG to develop AMPK activators to treat Type-2 diabetes and obesity. In June 2004, Aventis was acquired by Sanofi, and MTI re-acquired all of its intellectual property rights to AMP kinase as well as the rights to develop compounds identified during the collaboration. In October, 2004: MTI secured external financing from XL TechGroup, Inc. In Q4 2005, MTI demonstrated its first preclinical proof-of-principle of active compounds in a glucose tolerance test in mice.

For furthe
'/>"/>

SOURCE Mercury Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
2. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by type ... Plastic), by Application [GC, LC (HPLC, UHPLC, Flash ... analyses and studies the major market drivers, restraints, ... and Rest of the World. , Browse 90 ... 135 pages and in-depth TOC on “Chiral Chromatography ...
(Date:11/21/2014)... 21, 2014 , Todd ... Mariano Rodríguez es elegid vicepresidente senior de ... KLOX está en marcha para comenzar de forma rápida la ... de reciente aprobación en Europa   , ... al anunciar los siguientes nombramientos: Todd Martensen ...
(Date:11/21/2014)... Angeles, CA (PRWEB) November 20, 2014 ... “A Short Walk to the Other Side” published ... an “Award-Winning Finalist in the “Fiction: Short Story” category ... , Jeffrey Keen, President and CEO of USA Book ... from mainstream and independent publishers, including Simon & Schuster, ...
(Date:11/21/2014)... Fayetteville, Arkansas (PRWEB) November 20, 2014 ... partners, Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, ... equipment, announced that they have been selected to ... City of Fayetteville, Arkansas Paul R. Noland Wastewater ... feature BlueInGreen’s patented HyDOZ® gas dissolution ...
Breaking Biology Technology:Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4
... a Techne Corporation (Nasdaq: TECH ) Director and ... and Governance Committee, announced today that he is planning to ... 29, 2009. Techne,s shareholders reelect Directors on an annual ... for re-nomination as a Director for fiscal year 2010.Mr. Herbert ...
... PALO ALTO, Calif., May 19 Pioneering ... has secured clearance from the U.S. Food ... personal ultrasound device, the ,Signos,.(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/SF19276 ... for the first time makes it affordable ...
... Mode of ActionMOUNTAIN VIEW, Calif., May 19 ... from the company,s PROTECT-1 (the Prospective Randomized Oral ... clinical trial of Traficet-EN(TM) (CCX282-B) in patients with ... oral session at the upcoming 2009 Digestive Disease ...
Cached Biology Technology:Techne Corporation Announces the Retirement of G. Arthur Herbert, a Member of Its Board of Directors 2Signostics Receives FDA Clearance for World's Smallest Ultrasound Product 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... most common sensory disorder among the elderly. But scientists are ... contribute to the loss. Now a University of Florida ... institutions have identified a protein that is central to processes ... hearing loss. The findings help point the way toward ...
... by the U.S. Food and Drug Administration in patients ... invasiveness of ovarian cancer cells and also promoted their ... Cancer Center found. The drug, when paired with ... ovarian cancer in cell lines in which signaling of ...
... blooms of tiny marine plants called phytoplankton are flourishing in ... rapid melting of ice shelves and glaciers around the Antarctic ... climate change. As the blooms die back phytoplankton sinks to ... millions of years. Reporting this week in the ...
Cached Biology News:'Escaped' proteins add to hearing loss in elderly, UF researchers find 2'Escaped' proteins add to hearing loss in elderly, UF researchers find 3FDA approved leukemia drugs shows promise in ovarian cancer cells 2Antarctica glacier retreat creates new carbon dioxide store 2
... affinity chromatography, Affi-Prep protein A media ... remove IgG prior to analysis of ... complexes for antigen purification. Protein A ... immunoglobulins, especially IgG from mammalian species. ...
... introduce its new line of Protein Standards, ... for use in mass spectrometry, molecular biology, ... Standards are high quality purified proteins for ... by electrospray ionization mass spectrometry (ESI-MS). ...
... White solid. HYGROSCOPIC. A non-ionic ... reduced electrostatic interactions that do not interfere ... number: 8-16. Purity: ≥95% by HPLC. ... number 8 - 16, CMC 1.1 - ...
Determine relative degree of protein binding to phosphoinositides...
Biology Products: